 |  |  |  |  |  |
| Copyright 2006-2010 Abiant, Inc. |
Abiant Selected to Present at 2009 ADNI Investigators Meeting
Deerfield, ILLINOIS - - April 26, 2009 - - Work co-authored by members of Abiant and the New York
University School of Medicine was presented on April 26 at the 2009 Alzheimer's Disease
Neuroimaging Initiative (ADNI) Investigators Meeting in Seattle, Washington. The presentation, titled
"Regional Cerebral Glucose Metabolism at Baseline Predicts Symptom Onset in Normal ADNI
Subjects and Correlates to Disease Progression", focused on the results of analyses performed
using the neuroimaging scans in 250 patients in the ADNI database.
The results of this work showed that glucose metabolism levels declines in select regions of the
brain as subjects decline from Normal to Mild Cognitive Impairment stages and later Alzheimers
Disease. Since glucose metabolism is a primary source of energy for the brain, measurement of
glucose utilization in various brain regions using positron emission tomography (PET) imaging
provides a powerful way to "see", or measure, where activity in the brain is declining. One of the
earliest regions of decline is the hippocampus, a structure involved in encoding new memories.
Even in Normal subjects, decreased glucose metabolism activity can be seen well before the
subjects show symptoms.
A copy of the abstract is available by clicking here: ADNI Investigators Meeting 2009 Abstract.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Deerfield, ILLINOIS - - April 26, 2009 - - Work co-authored by members of Abiant and the New York
University School of Medicine was presented on April 26 at the 2009 Alzheimer's Disease
Neuroimaging Initiative (ADNI) Investigators Meeting in Seattle, Washington. The presentation, titled
"Regional Cerebral Glucose Metabolism at Baseline Predicts Symptom Onset in Normal ADNI
Subjects and Correlates to Disease Progression", focused on the results of analyses performed
using the neuroimaging scans in 250 patients in the ADNI database.
The results of this work showed that glucose metabolism levels declines in select regions of the
brain as subjects decline from Normal to Mild Cognitive Impairment stages and later Alzheimers
Disease. Since glucose metabolism is a primary source of energy for the brain, measurement of
glucose utilization in various brain regions using positron emission tomography (PET) imaging
provides a powerful way to "see", or measure, where activity in the brain is declining. One of the
earliest regions of decline is the hippocampus, a structure involved in encoding new memories.
Even in Normal subjects, decreased glucose metabolism activity can be seen well before the
subjects show symptoms.
A copy of the abstract is available by clicking here: ADNI Investigators Meeting 2009 Abstract.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
| Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030 |
| New and Events... |
Abiant News
 |
 |